Skip to main content
. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226

Fig 6.

Fig 6

Safety profiles in the subgroup analysis based on lung cancer (A) and melanoma (B). Each cell contains the pooled odds ratios and 95% credibility intervals for grade 1-5 adverse events or grade 3 or 4 adverse events; significant results are in bold. ICI=immune checkpoint inhibitor

HHS Vulnerability Disclosure